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BACKGROUND: Patients with permanent atrial fibrillation have poor outcomes, exercise capacity, and quality of life even on 
optimal anticoagulation. Based on mechanistic and observational data, we tested whether the mineralocorticoid receptor 
antagonist spironolactone can improve exercise capacity, E/e’ ratio, and quality of life in patients with permanent atrial fibril-
lation and preserved ejection fraction.
METHODS AND RESULTS: The double-masked, placebo-controlled IMPRESS-AF (Improved Exercise Tolerance in Heart Failure 
With Preserved Ejection Fraction by Spironolactone on Myocardial Fibrosis in Atrial Fibrillation) trial (NCT02673463) rand-
omized 250 stable patients with permanent atrial fibrillation and preserved left ventricular ejection fraction to spironolactone 
25 mg daily or placebo. Patients were followed for 2 years. The primary efficacy outcome was peak oxygen consumption on 
cardiopulmonary exercise testing at 2 years. Secondary end points included 6-minute walk distance, E/e’ ratio, quality of life, 
and hospital admissions. Spironolactone therapy did not improve peak oxygen consumption at 2 years (14.0 mL/min per kg 
[SD, 5.4]) compared with placebo (14.5 [5.1], adjusted treatment effect, −0.28; 95% CI, −1.27 to 0.71]; P=0.58). The findings 
were consistent across all sensitivity analyses. There were no differences in the 6-minute walking distance (adjusted treat-
ment effect, −8.47 m; −31.9 to 14.9; P=0.48), E/e’ ratio (adjusted treatment effect, −0.68; −1.52 to 0.17, P=0.12), or quality of 
life (P=0.74 for EuroQol-5 Dimensions, 5-level version quality of life questionnaire and P=0.84 for Minnesota Living with Heart 
Failure). At least 1 hospitalization occurred in 15% of patients in the spironolactone group and 23% in the placebo group 
(P=0.15). Estimated glomerular filtration rate was reduced by 6 mL/min in the spironolactone group with <1-unit reduction in 
controls (P<0.001). Systolic blood pressure was reduced by 7.2 mm Hg (95% CI, 2.2–12.3) in the spironolactone group versus 
placebo (P=0.005).
CONCLUSIONS: Spironolactone therapy does not improve exercise capacity, E/e’ ratio, or quality of life in patients with chronic 
atrial fibrillation and preserved ejection fraction.
REGISTRATION: UTL: https://www.clini caltr ial.gov; Unique identifier: NCT02673463. EudraCT number 2014-003702-33.
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Patients with permanent atrial fibrillation (AF) have poor outcomes and reduced quality of life even when they receive appropriate stroke prevention 
therapy and have preserved left ventricular function.1 
The prognosis is worse when maintenance of the sinus 
rhythm cannot be achieved and the patients progress 
to persistent or permanent AF, even on optimal rate 
control.2
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The mechanisms leading to reduced exercise 
capacity, related morbidity, and mortality in anti-
coagulated patients with permanent AF are likely 
related to disturbed diastolic ventricular function, 
myocardial fibrosis, and stiffening.3,4 In fact, activa-
tors of fibroblast signaling such as fibroblast growth 
factor 23 are elevated in patients with chronic AF.5 
These changes can lead to ventricular filling ab-
normality, reducing cardiac output, and decreasing 
exercise capacity.3,4 Aldosterone increases cardiac 
collagen deposition and left ventricular fibrosis.6 This 
involves direct stimulation of cardiac fibroblasts by 
aldosterone to produce collagen with chronification 
of oxidative stress and inflammation in the heart.7,8 
Cardiac expression of mineralocorticoid receptors is 
increased in AF, thus augmenting the genomic ef-
fects of aldosterone.9 According to a substudy of the 
RALES (Randomized Aldactone Evaluation Study) 
trial, the improved survival in patients with heart 
failure with impaired cardiac contractility treated by 
spironolactone was linked to its ability to reduce 
serum markers of ongoing fibrosis.10 The recently 
published RACE-3 (Routine Versus Aggressive 
Upstream Rhythm Control for Prevention of Early 
Persistent Atrial Fibrillation in Heart Failure Study), re-
porting a complex intervention that included spirono-
lactone (>75% difference in use between groups) 
suggested beneficial effects compared with usual 
care in patients with recent onset AF.11
The IMPRESS-AF (Improved Exercise Tolerance 
in Heart Failure With Preserved Ejection Fraction 
by Spironolactone on Myocardial Fibrosis in Atrial 
Fibrillation) trial therefore tested the effects of miner-
alocorticoid receptor inhibition with spironolactone in 
patients with permanent AF with preserved left ven-
tricular ejection fraction compared with placebo on 
exercise capacity (primary outcome); and its effect 
on quality of life, diastolic function, all-cause hospital 
admissions, and spontaneous cardioversion to sinus 
rhythm (secondary outcomes).
METHODS
The data that support the findings of this study will be 
made available, provided the request is scientifically 
sound and from an appropriately qualified research 
group. All requests for data should be addressed to 
the corresponding authors.
The IMPRESS-AF trial is a double-masked ran-
domized placebo-controlled multicenter enroll-
ment single-site management trial conducted in 
Birmingham, United Kingdom. The trial randomized 
250 patients with permanent AF and preserved left 
ventricular function 1:1 to either spironolactone or 
placebo. Permanent AF was defined as at least 1-year 
history of AF on all prescreening assessments with a 
previous decision to the accept rate control strategy 
and with further confirmation of AF on ECG at the 
screening. The previously published trial protocol was 
developed following the SPIRIT (Standard Protocol 
Items: Recommendations for Interventional Trials) 
statement and the latest PRO-specific guidance.12,13 
The study was approved by the National Research 
and Ethics Committee West Midlands—Coventry 
and Warwickshire (REC Reference 14/WM/1211). 
All patients provided signed informed consent. 
The study is registered at EudraCT number 2014-
003702-33 and Clini caltr ial.gov (NCT02673463). 
Because of the sensitive nature of the data collected 
for this study, requests to access the data set from 
qualified researchers trained in human subject con-
fidentiality protocols may be sent to the University of 
Birmingham.
Patients were recruited from primary care general/
family practices and outpatient AF clinics in Sandwell 
CLINICAL PERSPECTIVE
What Is New?
• The study presents a randomized placebo 
controlled clinical trial of spironolactone versus 
placebo in patients with chronic atrial fibrillation 
and preserved ejection fraction.
• Spironolactone therapy does not improve exer-
cise capacity, endothelial function assessed as 
echocardiographic E/e’ ratio, or quality of life in 
the tested population.
What Are the Clinical Implications?
• The trial does not support use of spironolactone 
therapy in patients with chronic atrial fibrillation 
and preserved ejection fraction.
Nonstandard Abbreviations and Acronyms
AF atrial fibrillation
BP blood pressure
IMPRESS-AF  Improved Exercise Tolerance in 
Heart Failure With Preserved 
Ejection Fraction by Spironolactone 
on Myocardial Fibrosis in Atrial 
Fibrillation
MLWHF  Minnesota Living with Heart 
Failure
NIHR  National Institute for Health 
Research
VO2peak peak oxygen consumption
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and West Birmingham Hospitals Trust, Birmingham. 
The patients were ≥50 years with permanent AF, left 
ventricular ejection fraction ≥55%, and controlled blood 
pressure (BP).14 An interpreter and translated materials 
were available if English was not their preferred lan-
guage. The exclusion criteria (full list published previ-
ously13) included life expectancy of <2  years, severe 
chronic obstructive pulmonary disease, severe mi-
tral or aortal valve stenosis or regurgitation, rapidly 
progressing or severe renal impairment, potassium 
≥5mmol/L, recent coronary artery bypass graft sur-
gery (within 3 months), use of aldosterone antagonist 
or potassium sparing diuretic within 14  days. All pa-
tients received optimized treatment following estab-
lished clinical guidelines on management of AF, heart 
failure, and hypertension.15
All patients were screened, investigated, and 
managed in the Research Clinic in the Institute of 
Cardiovascular Sciences, City Hospital, Birmingham. 
During the baseline visit, eligible patients underwent car-
diopulmonary exercise testing using a cycling ergom-
eter to measure peak oxygen consumption (VO2peak), 
6-minute walk test, and completed paper-based qual-
ity of life questionnaires (validated Minnesota Living 
with Heart Failure16 and EuroQol-5 Dimensions, 5-level 
version quality of life17 questionnaires). A block random-
ization (block size of 4) was performed after the as-
sessments using a secure web-based randomization 
system. Patients were stratified by their baseline VO2peak 
of ≤16 and >16 mL/min per kg. Patients, the trial team, 
care providers, outcome assessors, and data analysts 
were masked to the treatment allocation. Patients at-
tended the research clinic every 3 months for follow-up 
(Table S1). The day-to-day management of the trial was 
coordinated by the Birmingham Clinical Trials Unit, reg-
istered by the National Institute for Health Research 
(NIHR) as a trials unit. A Trial Steering Committee was 
responsible for overseeing the progress of the trial. An 
independent Data Monitoring and Ethics Committee 
was responsible for the regular monitoring of trial data 
and adverse events.
Patients randomized to spironolactone received 
25 mg once daily for 2  years. In the case of an in-
crease in potassium level to 5.1 to 5.5  mmol/L or 
non-life-threatening side effects (eg, gynecomastia) 
the dose was down-titrated to 25 mg each second 
day with an attempt to re-up-titrate the dose if the 
reason for down-titration has resolved. When potas-
sium levels exceeded 5.5  mmol/L or if toxicity was 
suspected, the trial medication was stopped for the 
duration of the trial, but the patients were requested 
to attend the remaining follow-up visits and their out-
comes were included in the intention-to-treat anal-
ysis. Patient compliance to treatment was defined 
adequate when ≥80% of allocated capsules were 
taken.
The primary hypothesis was assessed by the dif-
ference between trial groups in VO2peak on cardio-
pulmonary exercise testing18,19 at 2  years, adjusted 
for the baseline values. The Secondary efficacy end 
points were 6-minute walk test distance, quality of 
life using Minnesota Living with Heart Failure, and 
EuroQol-5 Dimensions questionnaires, diastolic func-
tion assessed by E/E’ ratio20,21 on echocardiography, 
rates of all-cause hospital admissions and sponta-
neous return to sinus rhythm on ECG. Prespecified 
safety outcomes were occurrence of breast pain or 
swelling, allergic reaction, raised serum creatinine 
(>220  μmol/L), low estimated glomerular filtration 
(<30  mL/min per 1.73m2), and hyperkalemia (≥5.1 
and ≥6.0 mmol/L).
Statistical Analysis
All primary analyses followed modified intention 
to treat principles including all patients report-
ing outcomes regardless of their compliance with 
the medication. For the primary outcome patients 
who died before the 2-year follow-up assessment 
were additionally included with VO2peak scores at 
2  years imputed as 0 regardless of cause; 3 sen-
sitivity analyses were undertaken for the primary 
outcome (further details are available in Data S1). 
Further analyses included additional adjustments 
for age, sex, and body mass index at baseline. Pre-
defined subgroup analyses compared the difference 
in primary outcome VO2peak between spironolactone 
and placebo according to VO2peak; age, sex, body 
mass index, systolic and diastolic BP. Details of 
the statistical methodology for the secondary out-
come measures are available in Data S1. Analyses 
of the study outcomes were defined in a statistical 
analysis plan, signed off before unmasking. Results 
are presented in accordance with CONSORT and 
CONSORT PRO.22 STATA version 12 software was 
used for all analyses.
Sample Size
Sample size was determined to be able to show a clini-
cally important difference in the primary outcome of 
VO2peak. Published values of VO2peak in subjects with 
heart failure give baseline values (mean 16 [SD 5] mL/
min per kg).23 A difference of 2  mL/min per kg was 
judged to be clinically relevant. A sample size of 100 
patients in each arm would give the power of at least 
80% to detect differences in primary and secondary 
end points of a magnitude consistent with published 
results from similar studies. We increased the sample 
size to 125 per arm for provision for a 20% dropout 
rate. Statistical power would be higher with the ben-
efits of adjusting for baseline values.
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RESULTS
A total of 250 patients were randomized to spirono-
lactone or placebo (125 per group). Patients were 
elderly (mean age, 72.3 [SD, 7.4] years, further de-
tails in Table  1). Random groups were well bal-
anced (Table  1). The final study visit was attended 
by 101 (81%) patients randomized to spironolactone 
and 106 (85%) randomized to placebo (Figure  1). 
Spironolactone had the expected effect on BP 
and kidney function. Systolic BP was reduced by 
7.2  mm  Hg (95% CI, 2.2–12.3) in the spironolac-
tone group, almost no change in the placebo group 
(Table S2). There was no significant treatment effect 
for diastolic BP. Spironolactone increased creatinine 
(mmol/L) by 6.9 (95% CI, 3.4–10.5) and lowered esti-
mated glomerular filtration rate (mL/min per 1.73) by 
6.0 (95% CI, −9.3 to −2.8) at 2 years.
Data on the primary outcome, VO2peak at the 
end of the trial were available for 106 patients in 
placebo group and 103 patients in spironolactone 
group (Table 2), which included 3 deaths in placebo 
group and 5 deaths in spironolactone group. In both 
groups, 3 patients were not able to perform cardio-
pulmonary exercise testing because of frailty. In the 
primary intention to treat analysis, VO2peak (mL/min 
per kg) changed from mean 14.5 (SD 4.6) to mean 
14.0 (SD 5.4) in the spironolactone group and from 
mean 14.6 (SD, 5.1) to mean 14.5 (SD, 5.1) in placebo 
group. The treatment effect showed no difference 
between the groups (differences in mean −0.28, 
95% CI, −1.27 to 0.71; P=0.58). The findings were 
Table 1. Baseline Characteristics
Spironolactone 
(n=125)
Placebo 
(n=125)
Demographic characteristics
Age, y 73 (68–77) 72 (67–78)
Sex
Women 28 (22%) 31 (25%)
Men 97 (78%) 94 (75%)
Ethnicity
White 118 (94%) 118 (94%)
Black 3 (2%) 3 (2%)
Asian 3 (2%) 2 (2%)
Ethnicity other than White, 
Black, or Asian or mixed 
ethnicity of White, Black and/
or Asian background
1 (1%) 2 (2%)
Smoker
Current smoker 6 (5%) 8 (6%)
Ex-smoker 66 (53%) 68 (54%)
Never smoked 53 (42%) 49 (39%)
Alcohol use, units/wk 3 (0–12) 6 (0–14)
Characteristics of the study outcomes
VO2peak, mL/kg per min 14 (11–18) 14 (11–18)
VO2peak of ≤16 mL/kg per min 77 (62%) 78 (62%)
6-min walk test, m 266 (196–316) 271 (200–330)
E/E’ ratio 9.8 (8.0–12.0) 9.7 (7.5–13.0)
E/E’ ratio categories
<10 66 (52.8%) 64 (51.2%)
≥10 to <14 41 (32.8%) 39 (31.2%)
≥14 18 (14.4%) 22 (17.6%)
EQ-5D-5L
Score 0.84 (0.74–0.94) 0.88 (0.74–0.94)
Missing data 4 (3%) 5 (4%)
MLWHF score
Score 7.0 (6.3–35.8) 14.0 (5.8–30.0)
Missing data 8 (6%) 4 (3%)
Clinical characteristics
Left ventricular ejection fraction (%) 58 (57–62) 58 (56–63)
Brain natriuretic peptide, pg/mL 122 (73–230) 136 (82–241)
Brain natriuretic peptide 
>130 ng/L
56 (44.8%) 66 (52.8%)
Body mass index, kg/m2 29 (26–33) 30 (26–34)
Systolic blood pressure, mm Hg 130 (117–140) 129 (118–142)
Diastolic blood pressure, mm Hg 75 (67–83) 74 (68–82)
Resting heart rate, bpm 85 (74–99) 83 (74–97)
Diabetes mellitus 24 (19%) 21 (17%)
Medications
Non-vitamin K oral 
anticoagulants
60 (48%) 57 (46%)
Vitamin K antagonists 47 (38%) 47 (38%)
Aspirin 10 (8%) 9 (7%)
Clopidogrel 6 (5%) 4 (3%)
(Continues)
Spironolactone 
(n=125)
Placebo 
(n=125)
Loop diuretic 25 (20%) 24 (19%)
Thiazide diuretic 14 (11%) 20 (16%)
Angiotensin-converting enzyme 
inhibitor or angiotensin receptor 
blocker
67 (54%) 80 (64%)
Calcium channel blocker 43 (34%) 37 (30%)
Beta blocker 66 (53%) 70 (56%)
Digoxin 26 (21%) 23 (18%)
Amiodarone 0 (0%) 1 (1%)
Statin 88 (70%) 69 (55%)
Inhalers of asthma or COPD 20 (16%) 17 (14%)
Continuous data presented as median (interquartile range). To score 
Minnesota Living with Heart Failure questionnaire, it was allowed that at most 
20% of 21 responses were missing which was equivalent to 4 data items. If 
there were ≤4 data items missing then we used mean substitution to impute 
the missing responses and then scored the questionnaire by summating 
the responses to all 21 questions; otherwise, the person’s score was left 
missing. EQ-5D-5L indicates EuroQol-5 Dimensions, 5-level version quality 
of life questionnaire; COPD, chronic obstructive pulmonary disease; MLWHF 
indicates Minnesota Living with Heart Failure; and VO2peak, peak oxygen 
consumption.
Table 1. (Continued)
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consistent across the performed sensitivity analyses 
(Table 2, Table S3).
The subgroup analyses showed no significant in-
teraction of treatment with baseline VO2peak values 
(mL/min per kg, ≤16 versus >16, P=0.54), body mass 
index (kg/m2, <25 versus 25–30 versus ≥30, P=0.13), 
sex (P=0.91), median BP (P=0.36 for systolic BP 
and P=0.93 for diastolic BP), and E/E’ ratio (<10 ver-
sus 10–14 versus ≥14, P=0.73) (Table  3). There was 
a significant interaction between treatment and age: 
higher VO2peak values were observed in older patients 
randomized to spironolactone, but in younger pa-
tients in placebo group (P=0.03 for interaction). The 
magnitude of the differences was small, with the point 
estimates for the treatment effect in each subgroup 
being smaller than the pre-stated clinically important 
treatment effect.
There was no difference between random groups 
in any of the secondary outcomes (Table 2, Table S4). 
The findings remained consistent after adjustment 
of age, sex, and body mass index for all outcomes 
(Tables  S3 and S4). Spontaneous return to sinus 
rhythm on ECG performed at 2  years was uncom-
mon in both study groups (4 [4%] in placebo group 
and 8 [8%] in spironolactone group, P=0.21) (Table 4, 
Table S5). At least 1 hospitalization was observed in 
15% of patients in spironolactone group and 23% in 
placebo group (hazard ratio, 0.65; 95% CI, 0.36–1.17) 
(Table 4, Figure 2, Table S5). There was no significant 
difference in overall mortality, death from cardiac 
causes, hospitalizations because of cardiac causes, 
and rates of stroke and systemic thromboembolism 
between the study arms (Tables  S6 through S8). 
Patients in the spironolactone group had a higher 
occurrence of breast pain (17 versus 5 in controls), 
breast swelling (11 versus 4 in controls), and hyper-
kalaemia (≥5.1  mmol/L, 46 versus 17 in controls) 
(Table S6).
DISCUSSION
Mechanistic studies have demonstrated that eleva-
tion in cardiac filling pressures (estimated by E/e’ in 
this trial) contributes to pulmonary limitations and im-
paired VO2peak.
24,25 Treatment with spironolactone in 
the IMPRESS-AF study does not improve either exer-
cise capacity or quality of life in this cohort of stable 
patients with permanent AF with preserved ejection 
fraction despite lowering BP. CIs excluded clinically 
important effects. On the contrary, kidney function, 
Figure 1. CONSORT flow diagram.
EQ-5D indicates EuroQol-5 Dimensions, 5-level version quality of life questionnaire; FU, follow up; IMP, investigational medicinal 
product; and MLWHF, Minnesota Living with Heart Failure.
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assessed by estimated glomerular filtration rate, wors-
ened in patients randomized to spironolactone.
Clinical trials of the aldosterone antagonists spi-
ronolactone and eplerenone (RALES, EPHESUS 
[Eplerenone Post-AMI Heart Failure Efficacy and 
Survival Study], EMPHASIS-HF [Eplerenone Post–
Acute Myocardial Infarction Heart Failure Efficacy 
and Survival Study]) uniformly showed their clinical 
benefits in systolic heart failure. The IMPRESS-AF 
study conclusively demonstrates that use of an aldo-
sterone antagonist, spironolactone does not improve 
aerobic capacity, estimated filling pressures, or qual-
ity of life in patients with AF without systolic impair-
ment, and generally consistent with the overall lack 
of effect in patients with heart failure and preserved 
ejection fraction found in the ALDO-DHF (Aldosterone 
Receptor Blockade in Diastolic Heart Failure)26 and 
TOPCAT (Treatment of Preserved Cardiac Function 
Heart Failure with an Aldosterone Antagonist)27 trials. 
Of interest, in the ALDO-DHF trial of predominantly 
hypertension-related heart failure and preserved 
ejection fraction aldosterone inhibition reduced E/e’ 
but did not increase in VO2peak, and in another trial 
spironolactone improved VO2peak and reduced ex-
ercise-induced increase in E/e’ in a selected pop-
ulation of patients with heart failure and preserved 
ejection fraction that excluded patients with AF.26,28 
Of note, although the TOPCAT trial showed overall 
neutral results this may be confounded by the quality 
issues in Eastern Europe.29 In the IMPRESS-AF trial, 
the hospitalization rates were numerically higher in 
the placebo arm. A larger study that is powered for 
hospitalizations and cardiovascular death might pro-
duce other results, although such a study would be 
difficult to justify based on the overall results of spi-
ronolactone trials in patients with preserved ejection 
fraction.
Although patients receiving spironolactone had nu-
merically more cases of spontaneous return to sinus 
rhythm such cases were few in both study arms, the 
Table 2. Study Outcomes
Spironolactone Placebo Treatment Effect*
P Value*Mean (SD) n Mean (SD) n (95% CI)†
Primary outcome†
VO2peak, mL/kg per min 14.0 (5.4) 103 14.5 (5.1) 106 −0.28 (−1.27 to 0.71) 0.58
Primary outcome sensitivity analysis
Per protocol analysis:‡ VO2peak, mL/kg per min 14.8 (4.3) 57 14.9 (4.9) 77 0.21 (−0.78 to 1.21) 0.67
Complete case analysis: VO2peak, mL/kg per min 14.8 (4.5) 98 14.9 (4.6) 103 −0.09 (−0.86 to 0.68) 0.81
Multiple imputation method:§ VO2peak, mL/kg per min 13.4 (6.0) 
‖ 125 14.0 (5.5) ‖ 125 −0.53 (−1.57 to 0.51) 0.32
Adjusted for stratification variable and BNP level: 
VO2peak, mL/kg per min
14.0 (5.4) 103 14.5 (5.1) 106 −0.32 (−1.31 to 0.68) 0.53
Analysis removing patients who died and could 
not perform CPET (assigned to a peak VO2 of 0) at 
follow-up: VO2peak, mL/kg per min
¶
14.8 (4.6) 98 14.9 (4.6) 103 −0.09 (−0.86, 0.68) 0.81
Secondary outcomes
6-min walk test distance, m† 313 (108) 105 330 (112) 107 −8.47 (−31.9 to 14.9) 0.48
E/Eʹ ratio 9.00 (3.05) 101 9.72 (3.57) 106 −0.68 (−1.52 to 0.17) 0.12
Brain natriuretic peptide, pg/mL 179 (171) 101 186 (110) 105 4.95 (−28.3 to 38.2) 0.77
EQ-5D-5L score† 0.81 (0.26) 98 0.84 (0.21) 104 −0.008 (−0.06 to 0.04) 0.74
MLWHF score# 17.4 (22.7) 96 15.3 (20.4) 104 0.49 (−4.32 to 5.29) 0.84
BNP, brain natriuretic peptide; CPET indicates cardiopulmonary exercise testing; EQ-5D-5L, EuroQol-5 Dimensions, 5-level version quality of life questionnaire; 
MLWHF, Minnesota Living with Heart Failure; VO2peak, peak oxygen consumption.
*The mean differences between the spironolactone group and placebo group, 95% CIs, and the corresponding P values were estimated from linear 
regression models adjusting for the baseline continuous peak oxygen consumption score. In the sensitivity analyses additional adjustments were made for age, 
sex, and body mass index.
†A value of 0 was assigned to peak oxygen consumption, 6-minute walk test, and EuroQol-5 Dimensions, 5-level version quality of life questionnaire scores 
for those who died.
‡Per-protocol population was defined as ≥80% of capsules taken.
§Predictive Mean Matching imputation method was used to generate 20 imputed data sets. Data for participants in spironolactone group and placebo group 
were imputed separately. peak oxygen consumption, age, body mass index, systolic/diastolic blood pressure, 6-minute walk test, brain natriuretic peptide level, 
E/E’ ratio, EuroQol-5 Dimensions, 5-level version quality of life, Minnesota Living with Heart Failure scores at baseline and sex were included in the imputation 
model.
 ‖ SD estimates were obtained by multiplying the standard error by the square root of 125.
¶Total of 8 exclusions; 5 from spironolactone, and 3 from placebo.
#For Minnesota Living with Heart Failure questionnaire, score ranges from 0 to 105 with a higher score reflecting poorer quality of life; the highest value across 
the whole participants was assigned to those who died. All patients choose to use the English version of the questionnaires with only 1 proxy completion case 
recorded (placebo group is the reference group).
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difference was not significant statistically, and could 
therefore be a chance finding. The recently pub-
lished RACE-3 trial suggested that a complex inter-
vention including spironolactone was associated with 
a higher rate of sinus rhythm maintenance at 1 year 
(P=0.042).11 The RACE-3 intervention consisted of 
mineralocorticoid receptor antagonists, statins, an-
giotensin-converting enzyme inhibitors and/or angio-
tensin receptor blockers, and cardiac rehabilitation.11 
Among the targeted trial medicines, the mineralocor-
ticoid receptor antagonists showed the most promi-
nent contrast in use (85% in the treatment group and 
4% in the control group). Whilst the RACE-3 trial in-
dicated the mineralocorticoid receptor antagonists 
could help maintenance of the sinus rhythm in the 
recent onset AF, spontaneous return in sinus rhythm 
was infrequent in both arms of the IMPRESS-AF trial. 
The actual baseline VO2peak of 14.25 mL/kg per min-
ute was lower than the projected 16 mL/kg per min-
ute, possibly reflecting the background chronic AF, 
but this is unlikely to affect the study conclusions.
Overall, spironolactone was well tolerated. There 
were comparable rates of withdrawal from the study 
in the treatment and control groups. As expected, 
spironolactone reduced BP, thus demonstrating 
adequate overall compliance with the drug as con-
firmed by the expected effect. However, we found a 
safety signal as there was a reduction of 6.0 mL/kg in 
the estimated glomerular filtration rate over 2 years. 
These data indicate potential harm to the kidney 
caused by treating patients with AF with spironolac-
tone. However, most patients with pharmacological 
inhibition of renin-angiotensin-aldosterone system, 
including spironolactone have hemodynamically 
Table 3. Subgroup Analysis of the Primary Outcome
Analyses
Spironolactone Placebo
Treatment Effect 
(95% CI)*
Estimate of Difference 
(95% CI)*,†
P Value for 
Interaction*Mean (SD) n Mean (SD) n
Pre-specified subgroup analyses
Peak VO2, mL/min per kg
VO2 ≤16 11.2 (4.4) 60 11.9 (3.7) 63 −0.56 (−1.85 to 0.73) 0.64 (−1.38 to 2.66) 0.54
VO2 >16 18.1 (3.9) 43 18.2 (4.6) 43 0.07 (−1.47 to 1.62)
Age, y
Age ≤ median‡ 14.4 (6.3) 54 16.6 (4.8) 53 −1.40 (−2.76 to −0.05) 2.24 (0.28 to 4.20) 0.03
Age > median 13.7 (4.3) 49 12.3 (4.6) 53 0.83 (−0.55 to 2.22)
BMI, kg/m2
BMI <25 14.7 (3.9) 14 15.2 (4.9) 14 0.30 (−2.40 to 2.99) … 0.13
25 to <30 14.9 (6.5) 43 16.4 (5.0) 36 −1.59 (−3.21 to 0.02) −1.89 (−5.05 to 1.27)
BMI ≥30 13.0 (4.5) 46 13.0 (5.0) 55 0.58 (−0.85 to 2.00) 0.28 (−2.79 to 3.35)
Sex
Women 11.0 (3.7) 20 12.1 (2.9) 26 −0.41 (−2.54 to 1.72) 0.14 (−2.28 to 2.57) 0.91
Men 14.8 (5.5) 83 15.2 (5.5) 80 −0.27 (−1.39 to 0.86)
Systolic blood pressure, mm Hg
SBP ≤ median‡ 13.5 (6.2) 52 14.8 (5.2) 54 −0.71 (−2.10 to 0.68) 0.93 (−1.06 to 2.93) 0.36
SBP > median 14.6 (4.4) 51 14.0 (5.1) 51 0.23 (−1.19 to 1.64)
Diastolic blood pressure, mm Hg
DBP ≤ median‡ 13.5 (5.6) 54 13.7 (5.2) 58 −0.24 (−1.58 to 1.11) −0.09 (−2.08 to 1.90) 0.93
DBP > median 14.7 (5.1) 49 15.3 (5.0) 47 −0.33 (−1.78 to 1.12)
Post-hoc subgroup analysis
E/E’
E/E’ <10 15.3 (5.2) 56 15.1 (5.1) 58 −0.26 (−1.60 to 1.10) … 0.73
10 <14 13.0 (4.9) 34 13.9 (5.5) 30 0.06 (−1.75 to 1.85) 0.31 (−1.95 to 2.58)
E/E’ ≥14 11.2 (6.2) 13 13.4 (4.8) 18 −1.23 (−3.86 to 1.40) −0.97 (−3.93 to 1.99)
BMI indicates body mass index; DBP, diastolic blood pressure; and SBP, systolic blood pressure; and VO2peak, peak oxygen consumption; mean is unadjusted.
*The mean differences between the spironolactone group and the placebo group, 95% CIs, and the corresponding P values were estimated from linear 
regression models adjusting for the baseline continuous peak oxygen consumption score.
†The lower level was always treated as the reference group for the estimates of treatment difference apart from sex for which women were the reference 
group.
‡The median age is 72.58 years, median systolic blood pressure is 129 mm Hg, and median diastolic blood pressure is 74 mm Hg (placebo group is the 
reference group).
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mediated reductions in glomerular filtration rates.30 
These changes can be renal protective by decreas-
ing chronic glomerular hyperfiltration in patients with 
chronic kidney disease and they may have contrib-
uted the decrease in HF hospitalization that was 
observed in the TOPCAT trial. Not unexpectedly, a 
higher occurrence of breast pain/swelling and hy-
perkalemia was noted in the spironolactone group.
Limitations
The study outcomes were assessed by tests of physi-
cal capacity, but these tests could be inherently af-
fected by various musculoskeletal problems despite 
every effort to perform the tests until the limits of the 
cardiac reserve are reached. Although recognized 
questionnaires were used to assess quality of life, spe-
cific validation of the tests in the study population has 
not been done.
There was a relatively high drop-out rate in this 
study, and overall 16% of patients did not complete the 
primary outcome tests. However, the study power was 
estimated to allow 20% loss of the patients during fol-
low-up, and the validity of the findings was maintained. 
The study did not have power to reliably define effects 
of spironolactone on hard outcomes, such as hospital-
izations or return to sinus rhythm. However, given the 
detrimental effects of the drug on kidney function in 
this trial population further testing of spironolactone will 
need careful consideration.
Table 4. Secondary Outcomes: Return to Sinus Rhythm and Hospitalization for All Causes
Analyses at 2 y Spironolactone Placebo Odds Ratio (95% CI) P Value
Sinus rhythm, n (%)* n=101 8 (8%) n=106 4 (4%) 2.19 (0.64–7.52)† 0.21†
Hospitalization for all causes
Participants with at least 1 event, n (%) n=118 18 (15%)‡ n=123 28 (23%) 0.65 (0.36–1.17)§ 0.15§
Incidence rate (no. per 10 000 person-days) n=118 2.46 n=123 3.78
*Spontaneous return to sinus rhythm on ECG.
†The odds ratios, 95% CIs, and the corresponding P values were estimated from a logistic regression model, after adjustment for the continuous baseline 
peak oxygen consumption.
‡One first hospitalized event had no date and was excluded from the time-to-event analysis.
§The adjusted hazard ratio, 95% CIs, and the corresponding P values were estimated from a Cox regression model adjusting for the baseline continuous peak 
oxygen consumption score for the primary analysis (placebo group is the reference group).
Figure 2. Kaplan–Meier plot of time to first hospitalization. 
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CONCLUSIONS
Treatment with the aldosterone antagonist, spirono-
lactone in patients with permanent AF and pre-
served ejection fraction does not improve exercise 
tolerance, quality of life, and diastolic function. 
Furthermore, spironolactone leads to worsening of 
renal function which should be considered in this 
patient population and use of mineralocorticoid re-
ceptor antagonists may mandate closer monitoring 
of renal function.
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Data S1. 
 
The primary analysis followed modified intention to treat principles including participants 
regardless of their compliance with the medication. Participants with missing data for the final 
assessment were excluded except for those who died before the two-year follow-up assessment. 
For these participants, their peak VO2 scores at two years were imputed as zero values 
regardless of cause. Whilst the value of zero was not actually measured, it allowed inclusion 
of the patient in the study and it should be a suitable reflection of the health state of the patient.  
 
The following sensitivity analyses were undertaken:  
a) Per-protocol analysis: participants with ≥80% allocated capsules taken with a final follow-up 
assessment for peak VO2 (with zero imputed if they died as in the intention-to-treat analysis). 
Participants for whom compliance data could not be obtained were excluded from the per 
protocol analysis; 
b) Complete case analysis: participants who completed the two-year follow-up assessment; 
c) Multiple imputation: outcomes for participants within missing two-year follow-up 
assessment who had not died were imputed using a multivariate imputation approach, 
which filled in missing values in multiple variables iteratively by using chained equations 
that assumed an arbitrary missing data pattern. The Predictive Mean Matching (PMM)31 
method was implemented which produces imputed values that better match the observed 
values than linear regression models, especially when peak VO2 score were not normally 
distributed. Missing data for participants in the spironolactone group and the placebo group 
were imputed separately, which would allow unbiased estimates for any interaction effects 
between the treatment and any covariate in the analysis model. Baseline peak VO2, age, 
BMI, systolic and diastolic blood pressure, six minute walk test distance, BNP level, E/E’ 
ratio, EQ-5D-5L, MLWHF scores and sex were included in the imputation model and used 
to generate 20 simulated data-sets. Analyses were then performed on each set with the 
results combined using Rubin’s rules32 to obtain a single set of results. 
 
For all the above outcomes, secondary analyses had been repeated by including additional 
adjustments for age, sex and BMI at baseline. 
  
Analyses of secondary outcomes were performed on the modified intention to treat basis as for 
the primary outcome. For the six minute walk test, the analysis substituted a zero value for 
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those participants who had died before the two-year follow-up assessment regardless of causes. 
For EQ-5D-5L and Minnesota Living with Heart Failure questionnaire (MLWHF) at one year 
and two years, scores indicating the worst level of quality of life observed across the whole 
dataset were substituted for those who had died before the one-year and two-year follow-up 
assessment, respectively, regardless of causes, where a higher score reflecting poorer quality 
of life for MLWHF and better quality of life for EQ-5D-5L. For the MLWHF, if up to four of 
the 21 responses were missing mean substitution was used to impute the missing responses and 
compute the overall score; otherwise, the score was coded as missing. Analyses for the 
remaining secondary outcomes had been undertaken on complete cases only.  
 
The primary outcome analysis was undertaken using multiple linear regression including the 
baseline continuous continuous peak VO2 score and treatment group as covariates. Multiple 
linear regression was also used for the following continuous outcomes, adjusting for the 
corresponding baseline value of each outcome in addition to the baseline continuous peak VO2 
score (accounting the stratifying variable used in the randomization): 
• Exercise tolerance measured by six minute walk test walk test at two years 
• Quality of life measured by MLWHF and EQ-5D-5L at one and two years 
• Left ventricular diastolic function measured by E/E’at two years 
• Brain natriuretic peptide level at two years 
In all cases the treatment effect estimate was a difference in mean values (spironolactone – 
placebo) with the uncertainty in the estimate expressed using a 95% confidence interval. 
 
The following pre-defined subgroups at baseline were compared for the primary outcome peak 
VO2 by inclusion of an interaction term (treatment by subgroup) in the linear regression model 
in addition to their main effects and baseline continuous peak VO2 score.  
• Peak VO2 categories (mL/min/kg): <=16 vs >16 
• Sex: male vs female  
• Age groups (years): split at median 
• BMI groups (kg/m2): <25 (normal or underweight), 25 to <30 (overweight), and 
≥30 (obesity) 
• Systolic blood pressure groups (mmHg): split at median 
• Diastolic blood pressure groups (mmHg): split at median 
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Multiple logistic regression was carried out analysis of the spontaneous return to sinus rhythm 
on electrocardiogram at two years, adjusting only for baseline continuous peak VO2 score. An 
additional analysis was undertaken additionally adjusting for the log transformed BNP levels 
at baseline as this is known to be predictive of this outcome. The treatment effect estimate was 
an odds ratio (odds on spironolactone compared to placebo) with the uncertainty expressed 
using a 95% confidence interval. 
 
Cox regression model was used to analyse the time to hospitalisation event data (for any cause) 
over two years, adjusted for baseline continuous peak VO2 score. Data on participants who had 
not been hospitalised over the two-year period were censored at the date of their last visit 
attended for clinical events, those who died who or were lost to follow-up were censored on 
their last visit date if they had not been hospitalised. A Kaplan-Meier plot of time to the first 
hospitalisation of any cause was presented. The treatment effect estimate was a hazard ratio 
(hazard on spironolactone compared to placebo) with the uncertainty expressed using a 95% 
confidence interval. 
 
Major adverse clinical events, as listed below:  
• Death from all causes  
• Death from cardiac causes 
• Hospitalisation for cardiac causes  
• Stroke  
• Systemic thromboembolism 
were compared between the two treatment groups using Fisher’s exact test. 
 
Absolute changes in creatinine, estimated glomerular filtration rate, systolic blood pressure and 
diastolic blood pressure from baseline to two years were computed within each arm, and 
compared as a difference in mean change between arms (with statistical significance assessed 
using a t test) 
 
The following known safety issues with the intervention drug were assessed at each visit and 
reported by treatment arms: Formal comparisons had not been undertaken. 
• Estimated glomerular filtration <30 mL/min/1·73m2 
• Hyperkalaemia (≥5·1 mmol/L)  
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• Hyperkalaemia (≥6·0 mmol/L)  
• Creatinine >220 μmol/L 
• Breast pain  
• Breast swelling  
• Allergic reaction to the trial medication  
In addition, the spontaneously reported adverse events were classified by the principle 
investigator and chief investigator, and tabulated by treatment group. 
 
Stata version 12 software was used for all analyses. 
 
Sample size 
Sample size was determined to be able to show a clinically important difference in the primary 
outcome of peak VO2.Published values of peak VO2 in subjects with HF give baseline values (mean 16 
[SD 5] mL/min/kg)23 and data in HFpEF suggest that a difference of two mL/min/kg would be clinically 
relevant, and was used for the design of the recent Aldo-DHF study of spironolactone in patients with 
HFpEF, 95% of whom were free from AF.26, 33, 34 Unfortunately, the study by Cicoira et al,23 used for 
power calculation does not give a standard deviation of in peak VO2 but a similar trial, Edelmann et 
al35 provides that statistic (five mL/min/kg) and also reports a similar magnitude of the effect. A sample 
size of 100 participants in each arm would give the power of at least 80% to detect differences in 
primary and secondary endpoints of a magnitude consistent with published results from similar 
studies. We increased the sample size to 125 per arm for provision for a 20% drop out rate. Statistical 
power would be higher should this rate be too pessimistic, and with the benefits of adjusting for 
baseline values. 
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Table S1. Timeline of trial procedures and follow up schedule. 
   Follow-up 
Visit Screening Baseline Month 1 Month 3 Month 6 Month 9 Month 12 Month 15 Month 18 Month 21 Month 24 
  Additional visits were arranged to reassess potassium levels if patient’s blood results show a potassium level of >5·0 mmol/L 
Eligibility Check X X          
Informed consent X           
Relevant medical history taken  X           
Concomitant medication X X X X X X X X X X X 
Standard clinical examination including BP 
check 
X X X X X X X X X X X 
Clinical Biochemistry            
Full blood count X  X X X X X X X X X 
Renal function, potassium, sodium X  X X X X X X X X X 
HBA1c (for diabetics)  X           
Lipid levels X           
Electrocardiogram X          X 
Echocardiogram X          X 
Brain Natriuretic Peptide test X          X 
Randomisation  X          
Dispensing of study drug  X   X  X  X   
Cardiopulmonary exercise testing   X         X 
Six-minute walk test  X         X 
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Quality of life questionnaires (MLWHFQ 
and EQ-5D) 
 X     X    X 
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Table S2. Changes in clinical characteristics. 
Changes in clinical characteristics Spironolactone Placebo Mean difference 
(95% CI)1 
P-value* 
 mean (SD) n (%) mean (SD) n (%) 
Exploratory outcomes (changes in clinical characteristics) 
Serum creatinine 
Baseline 90 (23) 125 (100%) 90 (20) 125 (100%)   
24 months 99 (23) 101 (81%) 92 (21) 106 (85%)   
Change from baseline to 24 
months 
8.9 (13.8) 101 (81%) 2.0 (12.1) 106 (85%) 6.9 (3.4 to 10.5) 0.0002 
Estimated glomerular filtration rate 
Baseline 70 (16) 125 (100%) 69 (17) 125 (100%)   
24 months 64 (15) 101 (81%) 69 (14) 106 (85%)   
Change from baseline to 24 
months 
-6.8 (11.3) 101 (81%) -0.8 (12.3) 106 (85%) -6.0 (-9.3 to -2.8) 0.0003 
Systolic blood pressure 
Baseline 129 (16) 125 (100%) 130 (15) 124 (99%)   
24 months 123 (18) 101 (81%) 130 (16) 106 (85%)   
Change from baseline to 24 
months 
-6.7 (19.8) 101 (81%) 0.6 (17.0) 105 (84%) -7.2 (-12.3 to -2.2) 0.005 
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Diastolic blood pressure 
Baseline 76 (11) 125 (100%) 76 (14) 124 (99%)   
24 months 72 (11) 101 (81%) 74 (12) 106 (85%)   
Change from baseline to 24 
months 
-3.9 (12.2) 101 (81%) -1.3 (14.4) 105 (84%) -2.6 (-6.3 to 1.1) 0.17 
 
*The mean differences between spironolactone and placebo groups, 95% confidence intervals (CIs) and the corresponding p values were 
obtained using two sample t test (placebo group is the reference group) 
SD: standard deviation 
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Table S3. Study outcomes additionally adjusted for age, sex and BMI. 
Analyses of VO2peak at 2 years Spironolactone  Placebo Treatment effect p-value* 
 Mean (SD) n Mean (SD) n  (95% CI)*  
Primary outcome†       
VO2peak (mL/kg/min) 14.0 (5.38) 103 14.5 (5.16) 105 -0.32 (-1.32 to 0.68) 0.53 
Primary outcome sensitivity analysis       
Per protocol analysis:‡ VO2peak (mL/kg/min) 14.8 (4.32) 57 14.9 (4.92) 76 0.17 (-0.81 to 1.14) 0.73 
Complete case analysis: VO2peak (mL/kg/min) 14.8 (4.45) 98 14.9 (4.59) 102 -0.14 (-0.89 to 0.61) 0.71 
Multiple imputation method:§ VO2peak (mL/kg/min) 13.4 (6.04)5 125 14.0 (5.48)|| 125 -0.53 (-1.57 to 0.51) 0.31 
Secondary outcomes       
Six-minute walk test distance (m)# 313 (108) 105 331 (112) 106 -8.30 (-31.9 to 15.3) 0.49 
E/E’ ratio 9.00 (3.05) 101 9.69 (3.57) 105 -0.64 (-1.48 to 0.20) 0.13 
Brain natriuretic peptide (pg/mL) 179 (171) 101 187 (109) 104 4.37 (-28.5 to 37.3) 0.79 
EQ-5D-5L score 0.81 (0.26) 98 0.84 (0.21) 103 -0.004 (-0.05 to 0.04) 0.86 
MLWHF score** 17.4 (22.7)  96 15.3 (20.4) 103 0.27 (-4.60 to 5.14) 0.91 
 
VO2peak:  peak oxygen consumption; SD: standard deviation 
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*The mean differences between spironolactone group and placebo group, 95% confidence intervals (CIs) and the corresponding p values were 
estimated from linear regression models adjusting for the baseline continuous VO2peak score.  In the sensitivity analyses additional adjustments 
for age, sex and BMI were made. 
†A value of 0 was assigned to VO2peak score for those who died before the 2-year follow-up assessment  
‡Per-protocol population was defined as ≥80% of capsules taken across the full 2-year trial duration or up to the time of death 
§Predictive Mean Matching (PMM) imputation method was used to generate 20 imputed data-sets. Data for participants in spironolactone 
group and placebo group were imputed separately. VO2peak, age, BMI, systolic/diastolic blood pressure, six-minute walk test, BNP level, E/E’ 
ratio, EQ-5D-5L, MLWHF scores at baseline and sex were included in the imputation model. 
||Estimates of the standard deviation have been obtained by multiplying the standard error by the square root of 125 
#For 6-minute walk test, a value of 0 was assigned to those who died; for EQ-5D-5L score, a  value of 0 was assigned to those who died; for 
MLWHF questionnaire, the highest value across the whole participants was assigned to those who died 
**Minnesota Living with Heart Failure (MLWHF) questionnaire; score ranges from 0 to 105 with a higher score reflecting poorer quality of life.  
All patients choose to use the English version of the questionnaires with only one proxy completion case recorded for completion of the 
questionnaires. 
(Placebo group is the reference group) 
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Table S4. Quality of life scores at one year. 
Analyses Spironolactone Placebo Treatment effect 
(95% CI)* 
p-value* 
Mean (SD) n Mean (SD) n 
Primary analysis 
EQ-5D-5L score 0.82 (0.22) 106 0.84 (0.19) 111 -0.01 (-0.05 to 0.03) 0.63 
MLWHF score† 18.4 (20.9)  101 16.9 (17.8) 110 1.24 (-2.48 to 4.96) 0.51 
Secondary analysis (additionally adjusted for age, sex and BMI) 
EQ-5D-5L score 0.82 (0.22) 106 0.85 (0.18) 109 -0.008 (-0.05 to 0.03) 0.72 
MLWHF score† 18.4 (20.9) 101 16.3 (17.3) 108 1.35 (-2.40 to 5.10) 0.48 
 
*The mean differences between spironolactone group and placebo group, 95% confidence intervals (CIs) and the corresponding p values were 
estimated from linear regression models, after adjustment for the baseline continuous VO2peak score and the corresponding baseline score of 
the outcome measure for the primary analyses or additionally adjusted for age, sex and BMI for the secondary analyses 
SD: standard deviation 
†Minnesota Living with Heart Failure (MLWHF) questionnaire; score ranges from 0 to 105 with a higher score reflecting poorer quality of life.  
All patients choose to use the English version of the questionnaires with only one proxy completion case recorded for completion of the 
questionnaires. 
(Placebo group is the reference group) 
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Table S5. Secondary outcomes: return to sinus rhythm and hospitalization for all causes additionally adjusted for age, sex and BMI. 
Analyses Spironolactone Placebo Odds Ratio (95% CI) p-value 
Sinus rhythm, n (%)* n=101 8 (7.9%) n=105 4 (3.8%) 2.14 (0.62 to 7.35) † 0.23† 
Hospitalization for all causes 
Participants with at least one event, n (%) n=118 18 (15.3%)‡ n=121 27 (22.3%) 0.62 (0.34 to 1.14)§ 0.12§ 
Incidence rate (no. per 10000 person days) n=118 2.46 n=121 3.69 
 
*Spontaneous return to sinus rhythm on electrocardiogram after 2 years of treatment 
†The odds ratios, 95% confidence interval (CIs) and the corresponding p values were estimated from a logistic regression model, after 
adjustment for the continuous VO2peak and BNP level score at baseline for the primary analysis and additionally adjusted for age, sex and BMI 
for the secondary analysis 
‡One first hospitalized event had no date and was excluded from the time to event analysis 
§The adjusted hazard ratio, 95% confidence intervals (CIs) and the corresponding p values were estimated from a Cox regression model 
adjusting for the baseline continuous VO2peak score for the primary analysis and additionally adjusted for age, sex and BMI for the secondary 
analysis (placebo group is the reference group) 
(Placebo group is the reference group) 
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Table S6. Adverse events and serious adverse events. 
AEs/SAEs* 
Spironolactone 
(n=125) 
Placebo 
(n=125) 
P-value† 
All SAEs 
Total number of patients experiencing at least 
one SAE, n (%) 
23 (18.4%) 32 (25.6%)  
Total number of SAEs 27 42 0.22 
Prespecified major adverse clinical events (SAEs) 
 (n=1213) (n=1233)  
Death from all causes, n (%) 5 (4.1%) 3 (2.4%) 0.50 
Death from cardiac causes, n (%) 5§ (4.1%) 1 (0.8%) 0.12 
Hospitalization for cardiac causes, n (%) 2 (1.7%) 6|| (4.9%) 0.28 
Stroke, n (%) 0 (0.0%) 2 (1.6%) 0.50 
Systemic thromboembolism, n (%) 0 (0.0%) 1 (0.8%) 1.00 
Prespecified safety outcomes (AEs) 
Number of patients experiencing at least one episode 
Breast pain, n (%) 17 (14%) 5 (4%)  
Breast swelling, n (%) 11 (9%) 4 (3%)  
Allergic reaction, n (%) 2 (2%) 0 (0%)  
Hyperkalaemia (≥5.1 mmol/L), n (%) 46 (37%) 17 (14%)  
Hyperkalaemia (≥6.0 mmol/L), n (%) 3 (2%) 0 (0%)  
Serum creatinine ever >220 μmol/L, n (%) 1 (1%) 0 (0%)  
Estimated glomerular filtration < 30 
mL/min/1.73m2, n (%) 
8 (6%) 2 (2%)  
Total number of episodes 
Breast pain 40 9  
Breast swelling 26 10  
Allergic reaction 2 0  
Hyperkalaemia (≥5.1 mmol/L) 72 30  
Hyperkalaemia (≥6.0 mmol/L) 3 0  
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Serum creatinine >220 μmol/L 1 0  
Estimated glomerular filtration < 30 
mL/min/1.73m2 
8 2  
 
*All adverse events reported here were collected at follow up visits 
†P-values were obtained using Fisher's exact test for major adverse clinical events 
‡Six SAEs (occurred to 6 individuals) were missing on their adjudication results; therefore, 
the corresponding outcomes for major adverse clinical events were missing where 4 
participants were in Spironolactone group and 2 in Placebo group. Where applicable, these 
6 participants were not included in the Fisher's exact test and the corresponding percentage 
calculation 
§One participant died from cardiac causes but also had one SAE not adjudicated; so only 3 
participants were missing in Spironolactone group in this case and the denominator used for 
the percentage calculation was 122  
||One participant in Placebo group had 2 hospitalizations for cardiac causes; so only one SAE 
was counted here for this participant 
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Table S7. Number of hospitalizations per participant by treatment group. 
Number of hospitalizations  Spironolactone 
(n=125) 
Placebo 
(n=125) 
None, n (%) 106 (84.8%) 97 (77.6%) 
One, n (%) 17 (13.6%) 22 (17.6%) 
Two, n (%) 1 (0.8%) 5 (4.0%) 
Three, n (%) 1 (0.8%) 0 (0.0%) 
Four, n (%) 0 (0.0%) 1 (0.8%) 
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Table S8. Causes of death in the study patients. 
Spironolactone (all deaths – 5 Placebo all deaths – 3 
Sudden onset (deceased) Unresponsive in house, likely to be seizure 
Seizure AF E. coli septicaemia, Multi organ failure 
Myocardial infarction Intracranial bleeding 
Died due to complications of Bypass 
surgery 
 
Died of clostridium difficile bacterial sepsis  
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